Roberts Zachary 4

What Happened
Zachary Roberts, EVP of R&D at Allogene Therapeutics (ALLO), disposed of 26,269 shares on January 21, 2026 at $1.56 per share, for a total proceeds of $40,980. The sale was a tax-withholding "sell-to-cover" tied to the vesting of restricted stock units and was mandated by the company's equity plan — not a discretionary open-market trade.

Key Details

• Transaction date and price: 2026-01-21, 26,269 shares at $1.56 each (total $40,980).
• Filing date: Form 4 filed 2026-01-23 (timely under the two-business-day rule).
• Shares owned after the transaction: Not specified in the provided filing excerpt; see the Form 4 for full holdings.
• Footnote: F1 — Sale was to satisfy tax withholding obligations on RSU vesting (sell-to-cover); not a voluntary trade by the reporting person.
• Transaction code: S (sale); withholding tax code often reported as F on filings.

Context
Sell-to-cover transactions are routine administrative actions to meet tax obligations on vested awards and generally do not signal insider sentiment about the company's prospects. For retail investors, purchases or voluntary sales by insiders typically warrant more attention than mandated withholding sales. For full details, check the referenced Form 4 (Accession 0001851044-26-000003).